We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » AstraZeneca Continues Its Hit Parade With Yet Another Imfinzi Win
AstraZeneca Continues Its Hit Parade With Yet Another Imfinzi Win
AstraZeneca has scored another win with Imfinzi (durvalumab), showing that the checkpoint inhibitor in combination with standard chemotherapy improved both overall and progression-free survival for patients with advanced biliary tract cancer (BTC), a rare, aggressive disease with extremely low 5-year survival rates.